已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery

医学 SABR波动模型 外科 肺癌 临床终点 阶段(地层学) 随机对照试验 解剖(医学) 倾向得分匹配 放射治疗 内科学 波动性(金融) 金融经济学 生物 古生物学 经济 随机波动
作者
Joe Yujiao Chang,Reza John Mehran,Lei Feng,Vivek Verma,Zhongxing X. Liao,James William Welsh,Steven Hsesheng Lin,Michael S. O’Reilly,Melenda D. Jeter,Peter A. Balter,Stephen E. McRae,Donald A. Berry,John Victor Heymach,Jack A. Roth,Mara B. Antonoff,Wayne Lewis Hofstetter,Ravi Rajaram,David C. Rice,Boris Sepesi,Stephen G. Swisher
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (10): 1448-1457 被引量:324
标识
DOI:10.1016/s1470-2045(21)00401-0
摘要

A previous pooled analysis of the STARS and ROSEL trials showed higher survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early-stage non-small-cell lung cancer (NSCLC), but that analysis had notable limitations. This study reports long-term results of the revised STARS trial, in which the SABR group was re-accrued with a larger sample size, along with a protocol-specified propensity-matched comparison with a prospectively registered, contemporary institutional cohort of patients who underwent video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND).This single-arm prospective trial was done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) and enrolled patients aged 18 years or older with a Zubrod performance status of 0-2, newly diagnosed and histologically confirmed NSCLC with N0M0 disease (squamous cell, adenocarcinoma, large cell, or NSCLC not otherwise specified), and a tumour diameter of 3 cm or less. This trial did not include patients from the previous pooled analysis. SABR dosing was 54 Gy in three fractions (for peripheral lesions) or 50 Gy in four fractions (for central tumours; simultaneous integrated boost to gross tumour totalling 60 Gy). The primary endpoint was the 3-year overall survival. For the propensity-matching analysis, we used a surgical cohort from the MD Anderson Department of Thoracic and Cardiovascular Surgery's prospectively registered, institutional review board-approved database of all patients with clinical stage I NSCLC who underwent VATS L-MLND during the period of enrolment in this trial. Non-inferiority could be claimed if the 3-year overall survival rate after SABR was lower than that after VATS L-MLND by 12% or less and the upper bound of the 95% CI of the hazard ratio (HR) was less than 1·965. Propensity matching consisted of determining a propensity score using a multivariable logistic regression model including several covariates (age, tumour size, histology, performance status, and the interaction of age and sex); based on the propensity scores, one patient in the SABR group was randomly matched with one patient in the VATS L-MLND group using a 5:1 digit greedy match algorithm. This study is registered with ClinicalTrials.gov, NCT02357992.Between Sept 1, 2015, and Jan 31, 2017, 80 patients were enrolled and included in efficacy and safety analyses. Median follow-up time was 5·1 years (IQR 3·9-5·8). Overall survival was 91% (95% CI 85-98) at 3 years and 87% (79-95) at 5 years. SABR was tolerated well, with no grade 4-5 toxicity and one (1%) case each of grade 3 dyspnoea, grade 2 pneumonitis, and grade 2 lung fibrosis. No serious adverse events were recorded. Overall survival in the propensity-matched VATS L-MLND cohort was 91% (95% CI 85-98) at 3 years and 84% (76-93) at 5 years. Non-inferiority was claimed since the 3-year overall survival after SABR was not lower than that observed in the VATS L-MLND group. There was no significant difference in overall survival between the two patient cohorts (hazard ratio 0·86 [95% CI 0·45-1·65], p=0·65) from a multivariable analysis.Long-term survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains promising for such cases but multidisciplinary management is strongly recommended.Varian Medical Systems and US National Cancer Institute (National Institutes of Health).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
徐进完成签到,获得积分10
刚刚
子琤完成签到 ,获得积分10
1秒前
帅气恋风发布了新的文献求助10
1秒前
fusheng完成签到 ,获得积分0
1秒前
1秒前
俭朴舞仙完成签到 ,获得积分10
1秒前
笑点低剑封完成签到,获得积分10
2秒前
2秒前
一丁雨完成签到,获得积分10
2秒前
尘南浔完成签到 ,获得积分10
2秒前
77完成签到 ,获得积分10
2秒前
zzz完成签到 ,获得积分10
2秒前
厚德载物完成签到 ,获得积分10
3秒前
害羞的语芹完成签到 ,获得积分10
3秒前
科研小白人完成签到 ,获得积分10
3秒前
热情毛巾发布了新的文献求助10
3秒前
斯文的觅波完成签到 ,获得积分10
3秒前
认真问柳完成签到,获得积分10
3秒前
加减乘除完成签到,获得积分10
3秒前
haoshan完成签到 ,获得积分10
3秒前
权青曼完成签到,获得积分10
4秒前
你喜欢什么样子的我演给你看完成签到 ,获得积分10
4秒前
zero完成签到 ,获得积分10
4秒前
Xenomorph完成签到,获得积分10
4秒前
life的半边天完成签到 ,获得积分10
5秒前
5秒前
虚心的煎蛋完成签到 ,获得积分10
5秒前
gq完成签到 ,获得积分10
6秒前
搞怪代荷完成签到,获得积分10
6秒前
ADAB0002完成签到,获得积分10
6秒前
chen完成签到 ,获得积分10
6秒前
duzhi完成签到 ,获得积分10
7秒前
高大的怜晴完成签到 ,获得积分10
7秒前
曹兆发布了新的文献求助10
8秒前
快乐的树叶完成签到 ,获得积分10
8秒前
哈哈哈完成签到 ,获得积分10
8秒前
本轩完成签到 ,获得积分10
8秒前
123完成签到 ,获得积分10
8秒前
清爽绿海完成签到,获得积分10
8秒前
拟态橙完成签到 ,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189866
求助须知:如何正确求助?哪些是违规求助? 9577019
关于积分的说明 21851254
捐赠科研通 7787798
什么是DOI,文献DOI怎么找? 3435795
关于科研通互助平台的介绍 2559856
邀请新用户注册赠送积分活动 2482699

今日热心研友

注:热心度 = 本日应助数 + 本日被采纳获取积分÷10